Related Content
- Walgreens, Alliance Boots, AmerisourceBergen deal to benefit Good Neighbor Pharmacy
- Walgreens, Alliance Boots announce blockbuster partnership with AmerisourceBergen
- Yost leaves helm of AmerisourceBergen
- AmerisourceBergen acquires TheraCom from CVS for $250 million
- Walgreens, Alliance Boots and AmerisourceBergen help redefine economies of scale
VALLEY FORGE, Pa. — AmerisourceBergen on Friday reported revenue of $19.9 billion, up 2.9%, for the first quarter ended Dec. 31.
"In the December quarter, we delivered outstanding performance on top of exceptional performance last year,” stated David Yost, AmerisourceBergen CEO. “We had strong results in all of our business units, we benefited from successful generic drug launches and we continued to demonstrate expense and working capital discipline,” he said. "Our balance sheet remains strong, and we continue to have excellent financial flexibility. We are off to a solid start for the fiscal year, demonstrating the strength of our two growth drivers — generics and specialty pharmaceuticals."
AmerisourceBergen reaffirmed its expectations for fiscal year 2011 diluted earnings per share in the range of $2.31 to $2.41.

